Special Situations Case Study: Bausch Health

Bausch Health (BHC) is a Canada-based specialty pharma company that develops, manufactures, and markets a broad range of branded and generic pharmaceuticals, OTC products, and medical devices.

Key Metrics
RemainCo Total Leverage
Fixed Charge Coverage Ratio


BauschHealth Logo

Bausch Health is in the process of separating its eye health business (B+L) via a spin-off transaction. The transaction, if/when executed, would leave Bausch Health with an over-levered capital structure and a weak collection of supporting assets. A B+L separation in mid-2023 would significantly increase the probability of a medium-term bankruptcy filing by BHC.

Bausch Health launched an exchange offer in August 2022 for all series of senior unsecured notes for new secured notes. The transaction – which was intended to capitalize on deeply distressed trading levels of BHC’s senior notes – allowed for material, one-time leverage reduction, further facilitating the B+L separation.

Despite the exchange transaction and subsequent open market repurchases of debt, we see little chance of BHC limping through its maturity calendar given foreboding walls in 2025-28. Attempts to navigate through upcoming maturities will be even more difficult if/when Xifaxan sees generic competition.


Canadian courts have a different process to the US for approving a spin-off transaction. BHC has been working to clear Canadian closing conditions, which include an independent solvency opinion.

BHC faces separate but related lawsuits in both federal and New Jersey courts tied to securities fraud and fraudulent transfer claims. Those suits could require BHC to settle in order to move forward with the B+L separation.

BHC is appealing a 2022 patent ruling with respect to its largest drug, Xifaxan, which accounts for ~40% of BHC total revenues and an even greater percentage of adjusted EBITDA. An adverse appeal ruling could allow for generic competition come 2024/25.

Bausch Health Chart

How We Help

Our team of over 150 analysts, lawyers, and journalists work together to provide our clients with the news and insights that can quickly change the valuation of names like BHC. ​

CreditSights’ dedicated team of special situations analysts provide deep-dive analysis to the most complex credits in the market, such as BHC. Leveraging our sector analysts’ expertise, our team’s insights and knowledge are unmatched by other research providers, and will help you make well-informed credit decisions.

BHC has been on our radar since 2020, but it was early August 2021 that the CreditSights team started to cover this credit more closely, detailing separation risks and with a recommendation to maintain U/P on long-dated unsecured notes. Our LFI team continued to cover breaking news and provide timely updates on the most important milestones, such as the debt starting to plunge on the Xifaxan patent ruling.

More recently the Covenant Review team of lawyers produced FAQ’s on the B+L IPO, credit agreements and analyzed incremental investments capacity. 

CreditSights allows you to dig deeper still into a particular credit and mine our data. Downloadable models, recovery analysis, and detailed capital structures are available, along with all archived news and research around these special situations and other credits in your portfolio.


If you want to stay informed about this exchange offer and better understand participation levels, valuation, and implications for BHC’s financial metrics, then be sure to add the company to your Watchlist on the new CreditSights platform.

Bausch Health Company Page

Request a Demo

Don’t have access to CreditSights, Covenant Review, LevFin Insights news or our Special Situations content? If you're interested in our latest analysis on BHC, we encourage you to request a demo. Just complete this form and we’ll get back to you.